跳至主要内容
临床试验/JPRN-UMIN000046820
JPRN-UMIN000046820已完成未知

A NON-INTERVENTIONAL OBSERVATIONAL STUDY OF EFFECTIVENESS AND SAFETY OF NIVOLUMAB PLUS CHEMOTHERAPY FOR UNTREATED ADVANCED RECURRENT GASTRIC CANCER - G-KNIGHT

Bristol-Myers Squibb K.K. Ono Pharmaceutical CO.LTD.0 个研究点目标入组 500 人开始时间: 2022年2月3日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • To participate in this study, the following criteria MUST NOT be met at the time of informed consent: 1.Patients who have been treated with antineoplastic agents as first-line treatment for advanced or recurrent gastric cancer prior to the initiation of nivolumab plus chemotherapy (patients who have received prior perioperative chemotherapy and patients who have received prior bisphosphonates for osseous metastases may be enrolled). 2.Patients who have been confirmed to be positive for HER2. 3.Patients who have been diagnosed with gastric cancer and have previously received investigational drugs with anti-tumor effects for gastric cancer. 4.Patients who were initiated with nivolumab plus chemotherapy as the first-line treatment for advanced or recurrent gastric cancer at a site other than the study site and were later hospitalized at the study site. 5.Other patients judged by the investigators to be inappropriate for enrollment in this study.

研究者

发起方
Bristol-Myers Squibb K.K. Ono Pharmaceutical CO.LTD.

相似试验